OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 15:39:49 2024-05-24 EDT | ||
| 8.44 EUR | -5.06% |
|
| Current month | -40.70% | ||
| 1 month | -37.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 8.51 | -4.27% |
| 24-05-23 | 8.89 | -4.82% |
| 24-05-22 | 9.34 | -4.69% |
| 24-05-21 | 9.8 | +6.06% |
| 24-05-20 | 9.24 | -2.01% |
Real-time Boerse Frankfurt Warrants
Last update May 24, 2024 at 03:39 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU513L |
| ISIN | DE000SU513L4 |
| Date issued | 2023-12-20 |
| Strike | 548 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.63 € |
|---|---|
| Lowest since issue | 8.44 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
